Article Information
History
- September 20, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- David M Favara, DPhil1,2,3,*,
- Karen McAdam, FRCP1,4,
- Anthony Cooke, PhD5,
- Alex Bordessa-Kelly, BSc6,
- Ieva Budriunaite, BSc7,
- Sophie Bossingham, MSc7,
- Sally Houghton, MSc8,
- Rainer Doffinger, PhD8,
- Nicola Ainsworth, PhD2 and
- Pippa G Corrie, PhD1
- 1Department of Oncology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge UK
- 2Department of Oncology, The Queen Elizabeth Hospital, The Queen Elizabeth Hospital King’s Lynn NHS Foundation Trust, Kings Lynn, UK
- 3Department of Oncology, University of Cambridge, Cambridge, UK
- 4Department of Oncology, Peterborough City Hospital, North West Anglia NHS Foundation Trust, Peterborough, UK
- 5Cambridge Clinical Laboratories, Cambridge, UK
- 6School of Clinical Medicine, University of Cambridge, Cambridge, UK
- 7Tissue Typing Laboratory, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge UK
- 8Department of Immunology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge UK
- ↵*Corresponding author: David M Favara (Email: df411{at}cam.ac.uk; Telephone: +441223245151)
Posted September 20, 2020.
SARS-CoV-2 antigen and antibody prevalence among UK staff working with cancer patients during the COVID-19 pandemic
